Source: https://patents.google.com/patent/BRPI0613138A2/en
Timestamp: 2019-12-08 11:27:56
Document Index: 138820096

Matched Legal Cases: ['art 17', 'art 18', 'art 18', 'art 16', 'art 17', 'art 1', 'art 1', 'art 17', 'art 17', 'art 17', 'art 18', 'art) 19', 'art) 21']

BRPI0613138A2 - Nebulizer - Google Patents
BRPI0613138A2
BRPI0613138A2 BRPI0613138-7A BRPI0613138A BRPI0613138A2 BR PI0613138 A2 BRPI0613138 A2 BR PI0613138A2 BR PI0613138 A BRPI0613138 A BR PI0613138A BR PI0613138 A2 BRPI0613138 A2 BR PI0613138A2
BRPI0613138-7A
Boehringer Engelheim Internat Gmbh
2005-06-24 Priority to DE102005029746.3A priority Critical patent/DE102005029746B4/en
2005-06-24 Priority to DE102005029746.3 priority
2006-06-23 Application filed by Boehringer Engelheim Internat Gmbh filed Critical Boehringer Engelheim Internat Gmbh
2006-06-23 Priority to PCT/EP2006/006047 priority patent/WO2006136427A1/en
2010-12-21 Publication of BRPI0613138A2 publication Critical patent/BRPI0613138A2/en
NEBULIZER. The present invention relates to a fluid nebulizer (1) (2) with a transport tube (9) for transporting fluid (2) and a method of producing a thick wall capillary are proposed. The transport tube (9) or capillary is of multipart and double wall construction and in particular is composed of a number of parts, such as an inner tube (23) and an outer tube (24). This allows the device to be manufactured more easily and economically, particularly when the internal diameters are very small.
Patent Descriptive Report for "NEBULIZER".
The present invention relates to a nebulizer according to the preamble of claim 1 and a method of producing a thick walled capillary.
A nebulizer available under the trade name "Respimat" in the form of an inhaler is known, as illustrated in its basic principle in WO 91/14468 A1 and in a specific embodiment in WO97 / 12687 A1 (Figures 6a, 6b), as well as 1 and 2 of the accompanying drawings. The nebulizer has a carrier device with a transport tube to transport and atomize the fluid. In particular, the transport tube is constructed as a thick-walled massive capillary as shown in FIG. 3b of WO 97/12687 A1. The transport pipe is therefore very difficult and complex to produce.
Capillaries with a small internal diameter and thin walls are generally obtainable. Capillaries with a thick wall and small manufacturing tolerances, however, are very difficult to produce and often have undesirable rough interior walls. This can be explained by the many stages of formation (which are often ultimately performed without a nucleus because of the small internal diameter) required to produce a massive thick-walled capillary.
In the present invention the term "capillary" refers in particular to preferably elongate microfluidic structures having a hydraulic diameter of less than 1000 μηπ, in particular preferably less than 500 μη. The inner cross section is preferably, but not necessarily, at least essentially round. The same is true in particular of the external contour of the capillary, preferably tubular or cylindrical. However, the capillary may also have other cross sections or non-round internal and / or external contours.
The term "thick wall" refers, according to the invention, to a capillary, particularly when the average inner diameter is less than 50% of the outer diameter, particularly less than 30% and / or when the wall thickness is more than 0.3 mm, preferably more than 0.5 mm.
The object of the present invention is to provide a mist having a transport tube and a method of producing a capillary, wherein the transport tube or capillary is simple and economical to produce with a thick wall construction, and particularly with a smooth inner wall, while having great stability.
The object is achieved by a nebulizer according to claim 1 or a method according to claim 35. Other advantageous features are cited in the auxiliary claims.
In one aspect, the present invention comprises the creation of a thick wall capillary or a nebulizer transport tube, preferably formed thereof with a double wall construction.
This allows the object to be produced more easily and therefore cheaper than in the prior art with low manufacturing tolerances. In particular, a smoother internal surface can be obtained. The double wall construction, in fact, makes it possible to use standard commercial thin-walled capillaries, so that the large number of formation steps that were previously required can be eliminated or reduced.
In particular, preferably, an inner tube is installed concentratively to an outer tube, particularly to form the transporter tube or thick-walled capillary. The tubes are then constructed, in particular, as thin-walled capillaries, which can be obtained cheaply and in a high quality.
The proposed thick-walled capillary is preferably used as a transport tube in a proposed nebulizer. The following discussion, therefore, will be directed primarily to the use of the capillary as a transport element or transport tube for a fluid that must be nebulized in such a nebulizer. However, thick-walled capillary can also be used for other purposes. This also applies to the method described for producing the transport tube or thick-walled capillary. Other advantages, characteristics, properties and aspects of the present invention will become apparent from the claims and the following description of preferred embodiments with reference to the drawings, wherein :
Figure 1 is a schematic section through a known nebulizer in the untensioned state;
Figure 2 is a schematic cross-section through the known tensioned nebulizer rotated through 909 compared to Figure 1;
Figure 3 is a schematic, non-scaled section through a proposed nebulizer with a transport tube according to a first embodiment;
Fig. 4 is a schematic section through a transport tube according to a second embodiment;
Fig. 5 is an enlargement of a detail of Fig. 4;
Fig. 6 is another enlargement of a detail of Fig. 4;
Fig. 7 is another enlargement of a detail of Fig. 4;
Figure 8 is a schematic, non-scaled cross-sectional view through a transport tube according to a third embodiment;
Fig. 9 is an enlargement of a detail of Fig. 8;
Fig. 10 is another enlargement of a detail of Fig. 8;
Figure 12 is a schematic, non-scale section through a transport tube according to a fourth embodiment;
Fig. 13 is an enlargement of a detail of Fig. 12;
Fig. 14 is another enlargement of a detail of Fig. 12;
Figure 15 is a schematic, non-scale section through a transport tube according to a fifth embodiment.
Fig. 16 is an enlargement of a detail of Fig. 15;
Figure 17 is a schematic non-scaled section through a transport tube according to a sixth embodiment.
Fig. 18 is an enlargement of a detail of Fig. 17; and
Figure 19 is a schematic non-scaled section through a transport tube according to a seventh embodiment. In the figures, the same reference numerals were used for identical or similar parts, resulting in corresponding or comparable properties and advantages, even if the associated description is not repeated.
Figures 1 and 2 show a nebulizer 1 known to atomize a fluid 2, particularly a highly effective pharmaceutical composition or the like, shown diagrammatically in the non-stressed state (Figure 1) and in the stressed state (Figure 2); The nebulizer 1 is constructed in particular as a portable inhaler and preferably operates without propellant gas.
When fluid 2, preferably a liquid, more particularly a pharmaceutical composition, is nebulized, an aerosol is formed which can be breathed or inhaled by a user (not shown). Usually, inhalation is at least once a day, more particularly several times a day, preferably at set intervals depending on the disease the patient is suffering from.
The known nebulizer 1 has an exchangeable and preferably exchangeable container 3 which contains fluid 2. The container thus forms a reservoir for fluid 2 to be nebulized. Preferably, container 3 contains an amount of fluid 2 or active substance that is sufficient to provide up to 200 dosage units, e.g., to allow up to 200 sprays or applications.
The container 3 is substantially cylindrical or cartridge-shaped and once the nebulizer 1 has been opened, the container can be inserted into it from below and exchanged if desired. Of rigid construction, fluid 2 is preferably contained in a fluid chamber 4 in the form of a foldable pouch in container 3.
Nebulizer 1 also has a carrier device, particularly a pressure generator 5 for conveying and nebulizing fluid 2, particularly in an optionally adjustable dosage amount.
Nebulizer 1 or pressure generator 5 has a holder 6 for container 3, an associated drive spring 7, shown only partially, with a locking element 8, which can be manually operated to release it, a transport tube 9, preferably , in the form of a thick-walled capillary, with an optional valve, particularly a non-return valve 10, a pressure chamber 11 and / or an expulsion nozzle 12 in the region of a mouthpiece 13. The container 3 is fixed to the nebulizer 1 through the holder 6, particularly by the locking fitting, so that the transport tube 9 penetrates the container 3. The holder 6 can be constructed such that the container 3 can be separated and exchanged.
As the drive spring 7 is axially tensioned, the bracket 6 with the container 3 and the transport tube 9 is moved downwards in the drawings and fluid 2 is drawn out of the container 3 through the non-return valve 10 in the pressure chamber 11 of the pressure generator 5.
During subsequent relaxation, upon actuation of the locking element 8, fluid 2 in the pressure chamber 11 is put under pressure as the transport tube 9, with its non-return valve 10 now closed, is moved back to above by relaxing the drive spring 7 and now acts as a ramming ram. This pressure forces fluid 2 through the expulsion nozzle 12 as a result of what is nebulized in an aerosol 14 as shown in Figure 1.
A user or patient (not shown) may inhale the aerosol14, while an air supply may be sucked into the mouthpiece 13 through at least one air supply opening 15.
The nebulizer 1 comprises an upper housing portion 16 and an inner portion 17 which is rotatable relative thereto (Figure 2) having an upper portion 17a and a lower portion 17b (Figure 1) while a particular manually operable housing portion 18 is. It is releasably fixed, in particular fitted to the inner part 17, preferably by means of a retaining element 19. In order to insert and / or replace the container 3, the housing part 18 may be detached from the nebulizer 1 .
The housing part 18 may be rotated relative to the upper housing part 16, leading therewith to the lower part 17b in the drawings. As a result, the drive spring 7 is tensioned in the axial direction by a gear (not shown) acting on the bracket 6. During tensioning, the container 3 is moved axially downwards until the container 3 assumes an extreme position as shown in figure 2. In this state, the drive spring 7 is under tension. When tensioning is performed for the first time, an axially acting spring 20 disposed in the housing portion 18 is supported at the base of the container and by means of a piercing member 21 or a container 3 or a bottom seal when first supported. in it for ventilation. During the nebulization process, the container 3 is moved back to its original position, shown in figure 1 by the drive spring 7, while the transport tube 9 is moved with its outlet end 22 in the pressure chamber 11.0 container 3 and the conveying element or conveying tube 9 thus performs a lifting movement during the tensioning or suction process of the fluid and during the atomization process.
The construction and mode of operation of various embodiments of a proposed nebulizer 1 and method will now be described in more detail with reference to the other non-scaled figures, but only emphasizing the essential differences of nebulizer 1 according to figures 1. and 2. The observations in FIGS. 1 and 2, therefore, therefore apply, or in an additional capacity, as long as any desired combinations of aspects of nebulizer 1 according to FIGS. 1 and 2 and nebulizer 1, according to the embodiments described herein. -written below or with each other are possible.
Figure 3 shows in schematic section the proposed container 3 and associated vaporizer part 1 according to a first embodiment. The transport tube 9 comprises an inner tube 23 and an outer tube 24, which are preferably concentrically arranged with one another. the other and / or formed as thin wall in particular standard commercial capillaries.
The transport tube 9 is thus double-walled and preferably multipart in construction and especially is in the form of a thick but preferably non-capillary wall. The construction of double and particularly multipart walls makes it possible, in particular, to manufacture the transport tube 9 and particularly more economically and / or precisely, more preferably, with a preferably smooth and / or round inner wall or contour.
Inner tube 23 forms a transport channel 25 within. The annular space 26 between the inner tube 23 and the outer tube 24 preferably forms a vent channel in the first embodiment. Alternatively, the annular chamber 26 may also preferably be hermetically sealed with gas.
The two pipes 23 and 24 are preferably firmly joined to each other by welding, for example, at the region of their ends. However, the two tubes 23 and 24 may also be joined together by some other method, for example by adhesive bonding, welding, deformation or the like.
The multipart construction of the transport tube 9 - of the two tubes 23 and 24, as explained above, or even more parts - may, if necessary, also be used independently of any ventilation, in particular in a nebulizer 1 of the type described. here before or some other nebulizer 1. In particular, the ventilation duct in the transport tube 9 may be omitted or, as already mentioned, sealed.
In the first embodiment, the transport tube 9 is preferably fixedly fixed to the support 6. In particular, the transport tube 9 or its outer tube 24 is provided for this purpose with a retention region 27 -. preferably having a corrugated outer contour or the like.
The carrier tube 9 is preferably injection molded with the bracket 6 in the retention region 27. The bracket 6 thus preferably engages with interlocking engagements in the retention region 27 or on the same. Thereby, the transport tube 9 is axially secured to the bracket 6 by interlocking engagement.
Preferably, the transport tube 9 or thick-walled capillary has a at least substantially smooth or cylindrical outer wall, which is optionally interrupted only by the retention region27, which is relatively short relative to length. in particular.
In the first embodiment, a dip tube 28, in particular, adjoins the transport tube 9 and preferably extends to the inner basement of the container 3. In the embodiment shown, the dip tube 28 is connected to a closure 30 of the container. container 3, in particular through a retaining portion 29 extending into a funnel shape, such that the transport tube 9 in the insert in the container 3 or when the closure 30 is perforated, may be inserted in the position shown in retention portion 29 of the dip tube 28 and a fluidic connection is established between the transport channel 25 and the dip tube 28.
However, the dip tube is optional only. As an alternative, this can also be omitted. The transport tube 9 then preferably extends into the bottom region of the container 3 or the fluid chamber 4.
The transport tube 9 is used in particular as a piston for pumping fluid 2 into the nebulizer 1 or the carrier or pressure generator 5. The transport tube 9 will have a relatively large external diameter. In contrast, the inside diameter of the transport tube 9 - that is, the inside diameter of the inner tube 23 or the transport diameter 25 thus formed - will be relatively small in order to obtain a small dead volume. Accordingly, it is necessary or at least desirable that the transport tube 9 be reasonably thick-walled - particularly in the sense described hereinafter and in the first instance this is achieved by concentrically disposing the inner tube 23 into the outer tube 24. In order to In order to achieve the desired pumping action and / or to ensure defined volumes or to avoid dead spaces, the annular space 26 between the inner tube 23 and the outer tube 24 is preferably closed at least at the end, and particularly of it is fluid-tight and more particularly preferably gas-permeable in the same manner.
The carrier tube 9 preferably comprises the valve, particularly the non-return valve 10, which in the embodiment shown is arranged at the downstream end of the carrier tube 9 or at the end extending into the pressure chamber 11.
Preferably, the transport tube 9 or thick-walled capillary consists at least essentially or entirely of metal, particularly stainless steel, more preferably austenitic nickel chromium steel.
Preferably, at least inner tube 23 and outer tube 24 consist of the same material, particularly metal or stainless steel, as previously mentioned.
Preferably, the transport tube 9 or thick-walled capillary has an outer diameter (of outer tube 24) of 1-2 mm and / or an inner diameter (of inner tube 23) of 0.1 - 0, 6 mm. Preferably, the outer diameter is at least two or three times as large as the inner diameter. The wall thicknesses of the tubes 23, 24 are preferably about 0.1 mm or less.
Preferably, the transport tube 9 or thick-walled capillary has a wall thickness (radial spacing of the inner wall of the inner tube 23 of the outer wall of the outer tube (24) of at least 0.3 mm). more preferably about 0.5 mm or more.
The proposed thick-walled or double-walled construction of the transport tube i goes beyond the preferred high displacement during its use as a piston and independently leads to a particularly high stability of the transport tube 9, which is necessary, for example, in order to permit safe and defined drilling or other type of open container 3 or the like. However, such stability can also be advantageous in other uses.
Other embodiments of nebulizer 1 or transport tube 9 or thick-walled capillary and preferred production of transport tube 9 or thick-walled capillary are described herein with reference to the other figures, while only essential difference of the first embodiment is explained, particularly. The above modalities therefore apply to a corresponding or additional capacity.
Figure 4 shows a second embodiment of the transverse pipe 9 in section. As in the first embodiment, the transport tube 9 is preferably made in two parts, namely the inner tube 23 and the outer tube24. Preferably, the two pipes 23, 24 are welded together. The annular space 26 between the pipes 23, 24 is preferably closed at both ends, particularly in a gas tight manner.
Figure 5 shows, in enlarged detail of figure 4, the valve or outlet end 22 of the transport tube 9. The valve, particularly a non-return valve 10, is preferably formed in the transport tube or tube 9. or integrated therein, as in the first embodiment. In the second embodiment, the outer tube 24 - as in the first embodiment - preferably forms a valve region 31 extending axially beyond the end of the inner tube 23, in particular where a valve element 32 of the valve is accommodated. The valve member 32 is preferably axially movable. The preferably bent end within or otherwise deformed 22 of the outer tube 24 or some other retaining means forms an axial stop to the outer notuboid valve element 32 or valve region 31 and delimits the axial mobility of the valve element 32 , in consequence.
The carrier tube 9 also preferably forms a valve seat 33 for valve 10 for valve body 32. Valve body 32 preferably sits axially on valve seat 33 when valve 10 is closed. , ie during the nebulization process.
In the second embodiment, the valve seat 33 is preferably formed by a concentric region or section of the outer tube 24, particularly a surrounding narrowing or rim 34. However, other constructive solutions are also possible.
The inner tube 23 preferably has a radially widening, particularly at least partially scenic, connecting portion, which in this case is formed at the end of the inner tube 23 and in particular expands at least substantially to the inner diameter of the outer tube 24. The two tubes 23, 24 are joined by the connecting portion 35, particularly by welding, gluing or the like. For example, it is possible to weld through the outer wall of the outer tube 24 in a substantially radial direction.
The inner tube 23 thus extends at least substantially to the valve seat 33 or to the narrowing or flange 34, thereby minimizing the volume through which fluid 2 can circulate in the transport tube 9 or in the flow channel. transportation 25.
Fig. 6 shows, in enlarged detail of Fig. 4, the other end of the transport tube 9. Here again, the inner tube 23 is preferably connected to the outer tube 24 via a widening disconnect portion 35. radially, in particular. In the embodiment shown, the inner tube 23 or its connecting portion 35 preferably terminates flush with the axial end of the outer tube 24 and is axially welded to the outer tube 24 in that particular region.
In the second embodiment, the inner tube 23 is preferably attached, particularly by welding, to the outer tube 24 at its two ends. The inner tube 23 may, however, also be radially connected to the outer tube 24 by spacers or other means between its two ends or may be at least radially supported or guided.
In the second embodiment, the annular space 26 (axial interstitial between the inner tube 23 and the outer tube 24) is preferably hermetically sealed, in particular in a fluid impermeable and gas impermeable manner.
In the second embodiment, the annular space 26 is preferably of hollow construction, that is, it is not filled with a medium. However, this is theoretically possible. For example, the gap 26 may be at least partially filled with an adhesive, an insulating material or some other suitable material.
In the second embodiment the transport tube 9 or outer tube 24 preferably has an outer diameter that remains at least substantially constant throughout its length. If required, the outer diameter of the valve region 10 may also be reduced. Retention region 27 may optionally project radially with respect to the aforementioned outside diameter as explained below.
Figure 7 shows, in enlarged detail of Figure 4, the retention region 27 of the transport tube 9. The retention region 27 is formed in the second embodiment by an outer radial projection 36, particularly in the form of a flange-like bent edge. Projection 36 or embroidered projecting radially outwardly with respect to the outside diameter of the transport tube 9 or outer tube 24. Preferably, the retention region 27 is for securing the transport tube 9 to bracket 6 by interlocking engagement. in the axial direction (see figure 3).
Figure 8 shows a third embodiment of the transport tube 9 in section. The fourth mode is very similar to the second mode and consequently only the main differences will be described below.
The carrier tube 9 is preferably once again made in two parts, namely inner tube 23 and outer tube 24.
Figure 9 shows in enlarged detail of figure 8 the inflow end of the transport tube 9. The inner tube 23 is preferably readjusted with its connecting portion 35 relative to the outer tube end 24. This makes Easier to adhere to the length tolerance of the transport tube 9.
Figure 10 shows, in enlarged detail of figure 8, the valve end 22 of the transport tube 9 (no terminal undulation without a valve element 32). The valve seat 33 is formed here by the axially expanding connecting portion 35 of the inner tube 23 at this end. Consequently, in this embodiment, the outer tube 24 preferably has no narrowing or lip 34 in this area.
Figure 11 shows, in enlarged detail of Figure 8, the retention region 27 of the transport tube 9. Instead of a projection, the retention region 27 in this fourth embodiment preferably has a radial indentation or recess 37, particularly an annual slot, step, lip or the like, several of which may be provided behind each other, and in particular a corrugated outer contour may be formed by the retention region 27.
In a particularly preferred aspect, the outer tube 24 in the retention region 27 is axially deformed inwardly so that it rests on the inner tube 23.
If necessary, the outer tube 24 in this contact region can also be fixedly connected to the inner tube 23, for example by welding or adhesive bonding. This may contribute to the overall stability of the transport tube 9.
However, it is also possible for a radial spacing to be maintained between outer tube 24 and inner tube 23 in the retention region 27.
Figure 12 shows a fourth embodiment of the transport tube 9 shown in section. The fourth embodiment is very similar to the second and third forms. In particular, the transport tube 9, according to each embodiment, is once again made in only two parts, preferably the inner tube 23 and the outer tube 24.
Figure 13 shows, in an enlarged detail of figure 12, the inflow end of the transport tube 9. The inner tube 23 or its connecting portion 35, in the fourth embodiment. It has a cylindrical portion 38 which is adjacent to the conical portion or radially extends from the connection portion 35 and has an outside diameter corresponding at least substantially to the inside diameter of the outer tube 24. The inner tube 23 is preferably impermeably connected the fluid is more preferably gas-tight to the outer tube 23 through the cylindrical portion 38, for example by welding, gluing or the like.
The cylindrical portion 38 or inner tube 23 is preferably also lowered inwardly or readjusted with respect to the associated end of outer tube 24 in the fourth embodiment as well.
Figure 14 shows, in an enlarged detail of figure 12, the valve or spill end 22 of tube 9 (without end bending and without a valve element (32)). In the fourth embodiment, the inner tube 23 preferably forms the valve region 31 of valve 10. In particular, the preferably at least substantially hollow cylindrical valve region 31 is directly adjacent to the conical connecting portion 35 of the inner tube. 23 forming the valve seat 33.
Preferably, the receiving region 31 has an outer diameter corresponding to the outer diameter of the outer tube 24. In this case, the outer tube 24 preferably terminates at the connecting portion 35 with the inner tube 23 and does not extend as far as the end of the tube. Valve conveying tube 9 as shown in Figure 14. If necessary, the outer tube 24 may taper conically at its end region to make it easier to connect it to the inner tube 23, for example by de-molding.
Figure 15 shows a fifth embodiment of the transport tube 9, in section. The fifth embodiment substantially corresponds to the fourth mode. The only difference is that at the inflow end the inner tube 23 is preferably connected via a separate spacer member 39 to the outer tube 24 as shown in Figure 19, which shows an enlarged detail of Figure 18. The element The spacer 39 is preferably at least substantially cylindrical hollow or glove shaped or annular in construction and closes the annular space 26 axially or at its extreme end. In particular, the radially widening connecting portion 35 in the inner tube 23 at the inflow end may be omitted. The two tubes 23 and 24 preferably terminate together with the spacer element 39 in an end plane or axial plane and are preferably axially welded thereto. However, the spacer element 39 may also be compressed into or on, glued or by some other method.
The spacer element 39 preferably has a wall thickness of at least substantially 50% of the difference between the inner diameter 24 and the outer diameter of the inner tube 23. The spacer element 39 is located in particular in a tight fitting or snap fitting. The spacer element 39 preferably has a length of less than 20%, particularly preferably less than 10% of the total length of the transport tube 9.
Alternatively, the spacer element 39 may also extend over a substantially longer length, in particular by increasing the defect resistance of the transport tube 9. For example, the spacer element 39 may also extend as far as the retention region 28 or even indentation or edge 34.
In the fifth embodiment, the transport tube 9 is no longer made in two parts, but preferably in three parts. Despite the larger number of parts, the fabrication is simpler, as the individual components can be manufactured simply, economically and with great precision.
Figure 17 shows a sixth embodiment of the transport tube 9 in section. The seventh mode is very similar to the fifth mode. However, in two parts, the transport tube 9 here is composed of three parts. The retention region 27 herein is preferably in the form of a surrounding annular crack or depression.
Figure 18 shows, in enlarged detail of Figure 17, the valve end 22 of the transport tube 9. The transport tube 9 in the next embodiment preferably has a valve element or connection element 40, which is produced in FIG. separately from inner tube 23 and outer tube 24 and forming the receiving region 31 of valve 10 and / or connecting the two tubes 23, 24.
The valve element or connecting element 40 in particular has a preferably conical connecting portion 35 adjacent to the receiving region 31, which connects the two pipes 23, 24 and / or once again forms the valve seat 33.
The outer tube 24 and the receiving region 31 of the valve element or connecting member 40 preferably preferably in turn have at least substantially the same external diameters as in the third and fourth embodiments. The outer tube 24 preferably terminates the connecting member 35 of the valve member or connecting member 40 as indicated in Figure 21, where the outer tube 24 is tightly joined to the connecting member 27, in particular by welding. If necessary, the outermost portion of the outer tube 24 may in turn be tapered.
Of correspondingly small diameter, preferably a glove-like or cylindrical connection region substantially 41 is contiguous with connection portion 35 and is pushed or engaged or compressed in inner tube 23 and secured thereto, particularly by welding.
In particular, the valve element or connection element 40 is constructed as a deep draw part which is relatively easy to produce.
Figure 19 shows a particularly preferred seventh embodiment of the transport tube 9 in section. Preferably, the transport tube 9 herein is comprised of at least four parts, namely the inner tube 23, the outer tube 24, the spacer element 39 and the valve or connecting element 40.
At the inflow end, the two tubes 23 and 24 are preferably connected via the spacer element 39, in particular as the sixth embodiment.
At the valve or outlet end 22, the two pipes 23 and 24 are preferably joined together by the valve member or connecting member 40, as in the seventh embodiment.
Despite the multitude of parts, namely at least four components, the seventh embodiment is relatively simple and economical to produce, particularly with low manufacturing tolerances and, if necessary, with a very smooth and even internal wall.
Initially, the valve element or connecting element 40 and the inner tube 23 are joined together, particularly by welding. In particular, it is preferable that the welding be performed radially outside in the connection region 41. In this way a first set is formed.
In addition, the outer tube 24 and spacer element 39 are joined together, particularly by welding, to form a second assembly. Welding is preferably carried out at the end face or at the inlet end.
Then the two sets are combined and firmly joined together. In particular, the outer tube 24 is welded to the valve element or connecting element 40. This can be essentially radially shaped. In addition, the spacer element 39 is fixedly connected to the inner tube 23, in particular axially. soldier at the same.
If the transport tube 9 is provided with optional valve 10, as shown, the valve element 32 (not shown) is then introduced into the valve region 10 and preferably secured by final deformation of the end 22 of the valve tube. conveyor 9 or of the valve member or connection member 40, particularly bent inwardly, to form an axial bearing for the valve member 32.
In the finished transport tube 9, the annular space 26 is preferably evacuated and / or gas tightly sealed. If necessary, annular space 26 may also be filled with a filler material, plastic or the like (not shown).
Valve element or connection element 40 or connection portion 35 preferably has a length of less than 20%, in particular less than 10% of the total length of the transport tube9. This makes production easier. The length of the transport tube 9or the outer tube 24 is preferably at least 50mm or 50 times the inner diameter.
The preferred multipart construction of the transport tube 9, consisting in particular of more than two parts, preferably three or four parts, may, if necessary, be implemented independently of the preferred double wall construction of the transport tube. 9. The valve 10 is more preferably formed by the valve element or connecting element 40, which is separately produced but still fixedly connected to the transport tube 9 and which in particular forms the receiving or valve region 31. for valve element 32 of valve 10.
In general, it will be noted that in the proposed nebulizer 1 the container 3 may preferably be inserted, i.e. incorporated into a nozzle 1. Therefore, the container 3 is preferably a separate component. However, the container 3 or the fluid chamber 4 may theoretically be formed directly by the nebulizer 1 or the vaporizer part 1 or may otherwise be integrated into or attached to the vaporizer 1.
As already mentioned, features, aspects and / or principles of the described embodiments may also be combined with each other as desired and may be used particularly in the known nebulizer according to Figures 1 and 2, but also in similar or different nebulizers.
Unlike free-standing or similar equipment, the proposed nebulizer 1 is preferably designed to be portable and in particular is a hand-operated mobile device.
The proposed solution can, however, be used not only in the nebulizers 1 specifically described herein, but also in other nebulizers or inhalers, for example, powder inhalers or so-called metered dose inhalers.
Nebulizer 1 is particularly preferably constructed as an inhaler, particularly for aerosol medical treatment.
Alternatively, however, nebulizer 1 may also be constructed for other purposes, preferably to nebulize a cosmetic and in particular liquid as a perfume atomizer. Container 3 therefore contains, for example, a pharmaceutical formulation or a liquid liquid such as perfume or the like. Further, the proposed capillary may also be used in any kind of any dispensing device, preferably for medical fluid 2. Thus, the term "nebulizer" should preferably be understood in that broad sense.
Preferably, fluid 2 is a liquid, as already mentioned, especially an aqueous or ethanol pharmaceutical formulation. However, it may also some other pharmaceutical formulation, a similar suspension, or particles or powder.
Preferred, preferably medical, fluid ingredients and / or formulations are listed hereinafter. As already mentioned, these may be aqueous or non-aqueous solutions, mixtures, formulations containing ethanol or solvent free formulations or the like. It is particularly preferable for fluid 2 to contain:
As pharmaceutically active substances, sub-substance formulations or mixtures of substances, all invaluable compounds used, such as, for example, invaluable macromolecules, as described in EP 1 003 478. Preferably, substances, sub-substance formulations or mixtures of substances, for example. treatment of respiratory and inhalation administered diseases are used.
Particularly preferred pharmaceutical compositions in this context are those selected from anticholinergics, betamimetics, steroids, phosphodiesterase IV inhibitors, LTD4 antagonists and EGFR kinase inhibitors, antiallergics, grass rust alkaloid derivatives, triptans, CGRP antagonists, phospho diesterase V inhibitors and combinations of these active substances, for example, more anticholinergic beta-mimetics or more antiallergic betamimetics. In the case of combinations, preferably at least one of the active substances comprises chemically bound water. Preferably anticholinergic-containing substances are used as monopreparations or in the form of combined preparations.
The following are mentioned as examples of the active ingredients or their salts:
Anticholinergics which may be used are preferably selected from tiotropium bromide, oxitropium bromide, deflutropium bromide, ipratropium bromide, glycopyrronium salts, trospium chloride, tolte-rhodine, trophenol 2,2-diphenylpropionate metobromide, -copine 2,2-diphenylpropionate, scopine 2-fluoro-2,2-diphenylacetate metobromide, tropenol 2-fluoro-2,2-diphenylacetate metobromide, tropenol 3,3 ', 4,4'-tetrafluorobenzylate methoxy , escopine metobromide 3,3 ', 4,4, -tetrafluorobenzylate, tropenol 4,4'-difluorobenzylate metobromide, eescopine metobromide 4,4'-difluorobenzylate, tropenol 3,3'-difluorobenzylate metobromide, escopine metobromide 3,3 '-difluorobenzylate, tropenol 9-hydroxy-fluorene-9-carboxylate methobromide, tro-penol metobromide 9-fluoro-fluorene-9-carboxylate, scopine metobromide 9-hydroxy-fluorene-9-carboxylate escobin 9-Fluoro-fluorene-9-carboxylate, tropenol metobromide 9-methyl fluorene-9-carboxylate, scopine methobromide 9-methyl fluorene-9-carboxylate, cyclopropyltropin benzylate metobromide, cyclopropyltropine 2,2-diinanylpropionate metobromide, cyclopropyltropine 9-hydroxy-xanthene methoxide 9-carboxylate, cyclopropyltropine metobromide 9-methyl fluorene-9-carboxylate, cyclopropyltropine metobromide 9-methyl-xanthene-9-carboxylate, cyclopropyltropine metobromide 9-hydroxy-fluorene-9-carboxylate, cyclopropyltropine metobromide methyl 4,4'-difluorobenzylate, tropenol 9-hydroxy-xanthene-9-carboxylate metobromide, scopine 9-hydroxy-xanthene-9-carboxylate escobin methoxide 9-methyl-xanthene-9-carboxylate tropenol metobromide scopine bromide 9-methyl-xanthene-9-carboxylate, triphenol metobromide 9-ethyl-xanthene-9-carboxylate, tropenol 9-difluoromethyl-xanthene-9-carboxylate metobromide, scopine 9-hydroxymethyl-xanthene 9-carboxylate, optionally in the form of racemic mixtures, enanciomerous diastereomers thereof and optionally in the form of their solvates and / or hydrates.
Betamimetics that may be used are preferably albuterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, indacaterol, isoetarin, isoprenalin, levosalbutamol, mabuterol, metauterol, meluprenene, meluterin, , pirbuterol, procatorol, reproterol, rimiterol, ritodrine, salmeterol, salmefamol, soterenot, sulfonterol, tiaramide, terbutaline, tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3- (4- {6- [2-hydroxy- 2- (4-hydroxy-3-hydroxymethyl-phenyl) -ethylamino] -hexyloxy} -butyl) -benzolsulfonamide, 5- [2- (5,6-diethyl-indan-2-ylamino) -1-hydroxy-ethyl] -8-hydroxy-1H-quinolin-2-one, 4-hydroxy-7- [2 - {[2 - {[3- (2-phenylethyl-yl) propyl] sulfonyl} ethyl] -amino} ethyl] -2 (3H) -benzothiazolone, 1- (2-fluoro-4-hydroxyphenyl) -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] ethanol, 1- [3- (4-methoxybenzylamino] ) -4-hydroxyphenyl] -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] ethanol, 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8 -il] - 2- [3- (4-N, N-dimethylaminophenyl) -2-methyl-2-propylamino] ethanol, 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2 - [3- (4-Methoxyphenyl) -2-methyl-2-propylamino] ethanol, 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3 - (4-n-butyloxyphenyl) -2-methyl-2-propylamino] ethanol, 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- {4- [3 - (4-methoxyphenyl) -1,2,4-triazol-3-yl] -2-methyl-2-butylamino} ethanol, 5-hydroxy-8- (1-hydroxy-2-isopropylaminobutyl) -2H-1,4- benzoxazin-3- (4H) -one, 1- (4-amino-3-chloro-5-trifluoromethylphenyl) -2-tert-butylamino) ethanol and 1- (4-ethoxycarbonyl-a-mino-3-cyano-5 -fluorophenyl) -2- (tert-butylamino) ethanol, optionally in the form of racemic mixtures, enantiomers or diastereomers thereof and, optionally, in the form of their pharmacologically acceptable acid addition salts, solvates and / or hydrates.
Preferred steroids are preferably selected from prednisolone, prednisone, butixocortpropionate, RPR-106541, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometa-sona, ciclesonide, rofleponide, ST-126, dexamethasone, dexamethasone. ) -fluoromethyl6a, 9oc-difluoro-17oc - [(2-furanylcarbonyl) oxy] -11 -β-hydroxy-1,6a-methyl-3-oxo-androsta-1,4-diene-17β-carbothionate, (S) - (2-oxo-tetrahydro-furan-3S-yl) 6a, 9a-difluoro-yl-p-hydroxy-16a-methyl-1-3-oxo-17a-propionyloxy-androsta-1,4-diene-17p-carbothionate and etiprednol dichloroacetate (BNP-166), optionally in the form of racemic mixtures, enanciomers or diastereomers thereof and optionally in the form of their salts and derivatives, solvates and / or hydrates.
PDE IV inhibitors that may be used are preferably selected from enprofillin, theophylline, roflumilast, aryl (cilomilast), CP-325,366, BY343, D-4396 (Sch-351591), AWD-12-281 (GW-842470 ), N- (3,5-dichloro-1-oxopyridin-4-yl) -4-difluoromethoxy-3-cyclopropylmethoxybenzamide, NCS-613, pumafentine, (-) p - [(4aRM06S *) - 9-ethoxy -1,2,3,4,4a, 10b-hexahydro-8-methoxy-2-methylbenzo [s] [1,6] naphthyridin-6-yl] -N, N-diisopropylbenzamide, (R) - ( +). 1- (4-bromobenzyl) -4 - [(3-cyclopentyloxy) -4-methoxyphenyl] -2-pyrrolidone, 3- (cyclopentyloxy-4-methoxyphenyl) -1- (4-N1- [N-2-cyano- S-methyl-isothioureido] benzyl) -2-pyrrolidone, cis [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylic acid], 2-carbomethoxy-4-cyano-4- (3 -cyclopropylmethoxy-4-difluoro-methoxyphenyl) cyclohexan-1-one, cis [4-cyano-4- (3-cyclopropyl-methoxy-4-difluoromethoxyphenyl) cyclohexan-1-ol], (R) - (H -) - ethyl [4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate, (S) - (-) - ethyl [4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate, CDP840, Bai-198004, D-4418, PD-168787, T-440, T-2585, Arophylline, Atizoram, V-11294A, CI-1018, CDC-801, CDC-3052, D-22888, IM-58997, Z-15370,9-cyclopentyl-5,6-dihydro-7-ethyl-3- (2-thienyl) -9H-pyrazolo [3,4-c] -1,2,4-triazolo [4,3-a ] pyridine and 9-cyclopentyl-5,6-dihydro-7-ethyl-3- (tert-butyl) -9H-pyrazolo [3,4-c] -1,2,4-triazolo [4,3-a] pyridin, optionally in the form of racemic mixtures, enantiomers or diaste rheomers thereof and optionally / in the form of their pharmaceutically acceptable acid addition salts, solvates and / or hydrates.
LTD4 antagonists that may be used are selected from montelukast, 1 - (((R) - (3- (2- (6,7-difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2- hydroxy-2-propyl) phenyl) thio) methylcyclopropane acetic acid 1 - (((1 (R) -3 (3- (2- (2,3-dichlorothieno [3,2-b] pyridin-5-yl) ) - (E) -ethenyl) phenyl) -3- (2- (1-hydroxy-1-methylethyl) phenyl) propyl) thio) methyl) cyclopropane acetic, pranlukast, zafirlukast, [2 - [[2- (4 -butyl-tert-2-thiazolyl) -5-benzofuranyl] oxymethyl] phenyl] acetic acid, MCC-847 (ZD-3523), MN-OI, MEN-91507 (LM-1507), VUF-5078, VUF- K-8707 and L-733321, optionally in the form of racemic mixtures, enantiomers or diastereomers thereof, optionally in the form of their pharmacologically acceptable addition salts and, optionally, in the form of their salts and derivatives, their solvates and / or hydrates.
EGFR kinase inhibitors which may be useful are preferably selected from cetuximab, trastuzumab, ABX-EGF, Mab ICR-62,4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[ 4- (morpholin-4-yl) -1-oxo-2-buteri-1-yl] amino} -7-cyclopropylmethoxy-quinazoline, 4 - [(R) - (1-phenyl-ethyl) amino] -6- {[4- (morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7-cyclopentyloxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] - 6 - {[4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7 - [(S) - (tetrahydrofuran -3-yl) oxy] quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [2 - ((S) -6-methyl-2-oxo-morpholin-4-yl ) -ethoxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluorophenyl) amino] -6- ({4- [N- (2-methoxy-ethyl) -N-methyl-amino] - 1-oxo-2-buten-1-yl} amino) -7-cyclopropylmethoxy-quinazoline, 4 - [(R) - (1-phenylethyl) amino] -6 - ({4- [N- (tetrahydropyran 4-yl) -N-methyl-amino] -1-oχο-2-buten-1-yl} amino) -7-cyclopropylmethoxy-quinazoline, 4 - [(3-chloro-4-fluorophenyl) amino] -6- ({4- [N- (2-methoxy-ethyl) -N-methyl-amino] -1-oχο-2-buten-1-yl } amino) -7-cyclopentyloxy-quinazoline, 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1-oxo-2-buten -1-yl] amino} -7 - [(R) - (tetrahydroturan-2-yl) methoxy] -quinazoline, 4 - [(3-ethin-1-phenyl) amino] -6,7-bis- (2 -methoxy-ethoxy) -quinazoline, 4 - [(R) - (1-phenyl-ethyl) amino] -6- (4-hydroxy-phenyl) -7H-pyrrolo [2,3-d] pyrimidine, 3-cyano -4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7-ethoxy-quinoline , 4 - [(R) - (1-phenyl-ethyl) amino] -6- {[4 - ((R) -6-methyl-1-2-oxo-morpholin-4-yl) -1-οχο-2 -buten- 1-yl] amino} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (morpholin-4-yl) -1-oxo-2 -buten-1-yl] amino} -7 - [(tetrahydrofuran-2-yl) methoxy] -quinazoline, 4 - [(3-ethynyl-phenyl) amino] -6- {[4- (5,5- dimethyl -2-oxo-morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- { 2- [4- (2-oxo-morpholin-4-yl) -piperidin-1-yl] -ethoxy} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4-amino-cyclohexa n-1-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4-methanesulfonylamino-cyclohexan-1-yloxy) -7 -methoxy-quinazoline, A - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-3-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro) phenyl) amino] -6- {1 - [(morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (piperidin-3-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [1- (2-acetylamino-ethyl) -piperidin-4 -yloxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7-ethoxy-quinazoline, 4 - [(3 -chloro-4-fluoro-phenyl) amino] -6- {trans-4 - [(morpholin-4-yl) carbonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline, 4 - [(3-chloro -4-fluoro-phenyl) amino] -6- {1 - [(piperidin-1-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro -phenyl) amino] -6- (cis-4- {N - [(morpholin-4-yl) carbonyl] -N-methylamino} -cyclohexan-1-yloxy) -7-methoxy-quinazoline, 4- [ (3-chlor o-4-fluoro-phenyl) amino] -6- (trans-4-ethanesulfonylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] - 6- (1-methanesulfonyl-piperidin-4-yloxy) -7- (2-methoxy-ethoxy) -quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [1- (2 -methoxy-acetyl) -piperidin-4-yloxy] -7- (2-methoxy-ethoxy) -quinazoline, 4 - [(3-ethynyl-phenyl) amino] -6- (tetrahydropyran-4-yloxy] -7- methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- {N - [(piperidin-1-yl) carbonyl] -N-methyl-amino} -cyclohexan -1-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {cis-4 - [(morpholin-4-yl) carbonylamino] -cyclohexan-1 -yloxy} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1- [2- (2-oxopyrrolidin-1-yl) ethyl] -piperidin-4 -yloxy} -7-methoxy-quinazoline, 4 - [(3-ethynyl-phenyl) amino] -6- (1-acetyl-piperidin-4-yloxy) -7-methoxy-quinazoline, 4 - [(3-ethynyl -phenyl) amino] -6- (1-methyl-piperidin-4-yloxy) -7-methoxy-quinazoline, 4 - [(3-ethynyl-phenyl) amino] -6- (1-methanesulfonyl-piperidin -4-yloxy) -7-methoxy-quinazoline, A - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-methyl-piperidin-4-yloxy) -7- (2-methoxy-ethoxy ) -quinazoline, 4 - [(3-ethin-1-phenyl) amino] -6- {1 - [(morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline, 4 - [( 3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(N-methyl-N-2-methoxy-amino) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-ethyl-piperidin-4-yloxy) -7-methoxy-quinazoline, A - [(3-chloro-4-fluoro-5-phenyl ) amino] -6- [cis-4- (N-methanesulfonyl-N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [cis-4- (N-acetyl-N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino ] -6- (trans-4-methylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [trans-1-4- ( N-methanesulfonyl-N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4- dimethylamino-cyclohexan-1-ylox i) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4- {N - [(morpholin-4-yl) carbonyl] -N-methyl -amino} -cyclohexan-1-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [2- (2,2-dimethyl-6-6-oxo- morpholin-4-yl) ethoxy] -7 - [(S) - (tetrahydrofiiran-2-yl) methoxy] quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1 -methanesulfonyl-piperidin-4-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-cyano-piperidin-4-yloxy) -7-methoxy -quinazoline, and 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(2-methoxyethyl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline, optionally in the form of racemic mixtures, enantiomers or diastereomers thereof, optionally in the form of their pharmacologically acceptable acid-forming salts their solvates and / or hydrates.
By acid addition salts, pharmaceutically acceptable acid salts which the compounds may possibly be capable of forming are, for example, salts selected from hydrochloride, hydrobromide, hydroiodide, hydrophosphate, hydrophosphate, hydromethanesulfonate hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate, preferably hydrochloride, hydrobromide, hydrosulfate, hydrophosphate, hydrofumarate and hydromethane
Examples of antiallergics are disodium cromoglycate, nedo-cromil.
Examples of grass rust alkaloid derivatives: dihydroergotamine, ergotamine.
For inhalation, pharmaceutical compositions, pharmaceutical formulations and mixtures including the active substances mentioned above, as well as salts, esters and combinations of these substances, salts and esters may be used.
1 nebulizer2 fluid3 container4 fluid chamber5 pressure generator6 bracket7 drive spring8 locking element9 transport tube10 non-return valve11 pressure chamber12 ejection nozzle13 mouthpiece 14 aerosol 15 air inlet opening 16 housing upper part 17 inner part 17a upper inner part 17b lower inner part 18 housing part (lower part) 19 retaining member 20 spring (on lower housing part) 21 piercing element 22 end (transport tube) 23 inner tube 24 tube external 25 transport channel 26 annular space 27 retention region 28 immersion tube 29 retention portion 30 closure 31 valve region 32 valve element 33 valve seat 34 lip 35 cylindrical portion 39 spacer element 40 connection member 41 connection region
1. Nebulizer (1) for a fluid (2) having a transport tube (9) for conveying the fluid (2), in particular the transport tube (9) being constructed as a wall capillary thick, characterized in that the transport tube (9) is of double wall construction.
Nebulizer according to claim 1, characterized in that the transport tube (9) comprises an inner tube (23) and / or an outer tube (24).
Nebulizer according to claim 2, characterized in that between the inner tube (23) and the outer tube (24) a particular hollow annular space (26) is formed, which is preferably sealed. gas-tight.
Nebulizer according to claim 2 or 3, characterized in that the inner tube (23) and the outer tube (24) extend concentric with respect to each other.
Nebulizer according to any one of claims 2 to 4, characterized in that the inner tube (23) is connected, particularly welded and / or glued, to the outer tube (24) by means of a portion. radially widening connection member (35), a spacer member (39) and / or a valve member or connector member (40).
Nebulizer according to claim 5, characterized in that the connecting portion (35) is preferably formed into one end of the inner tube (23).
Nebulizer according to claim 5 or 6, characterized in that the connecting portion (35) has an outer diameter corresponding at least substantially to the inner diameter of the outer tube (24).
Nebulizer according to one of Claims 5 to 7, characterized in that the connecting portion (35) ends flush with or behind the outer tube end (24).
Nebulizer according to any one of claims 5 to 8, characterized in that the connecting portion (35) has a conical region, which in particular forms a valve seat (33).
Nebulizer according to any one of claims 5 to 9, characterized in that the length of the connection portion (35) is less than 20%, in particular less than 10% of the length. overall length of the transport tube (9).
Nebulizer according to any one of claims 5 to 10, characterized in that the spacer element (39) and / or the valve element or the connecting element (40) are or are formed as components which are produced. separately from the inner tube (23) and the outer tube (24), particularly by deep drawing.
Nebulizer according to any one of claims 5 to 11, characterized in that the valve element or the connection element (40) is mounted on the end of the transport pipe (9) or inner pipe. (23) and / or the outer tube (24).
Nebulizer according to any one of claims 5 to 12, characterized in that the valve element or connecting element (40) comprises or forms a valve region (31) having an outer diameter which at least substantially corresponds to the outer diameter of the outer pipe (24) or transport pipe (9).
Nebulizer according to any one of claims 5 to 13, characterized in that the valve element or connecting element (40) comprises a conical region which in particular forms a valve seat. valve (33).
Nebulizer according to any one of claims 5 to 14, characterized in that the length of the valve element or connecting element (40) is less than 20%, in particular less than 10% of the total length. the transport tube (9).
Nebulizer according to any one of claims 5 to 15, characterized in that the spacer element (39) is a glove-shaped construction.
Nebulizer according to any one of claims 5 to 16, characterized in that the length of the spacer element (39) is less than 20%, more particularly less than 10% of the total length. the transport tube (9).
Nebulizer according to any one of claims 5 to 17, characterized in that the wall thickness of the spacer element (39) accounts for at least approximately 50% of the difference between the inner diameter of the outer tube ( 24) and the outer diameter of the inner tube (23).
Nebulizer according to any one of the preceding claims, characterized in that the transport tube (9) is composed of several parts, particularly by welding and / or adhesive bonding.
Nebulizer according to any one of the preceding claims, characterized in that the transport tube (9) or some or all parts of the transport tube (9) consist essentially of metal of preferably stainless steel, particularly nickel austinitic chrome.
Nebulizer according to any one of the preceding claims, characterized in that the transport tube (9) comprises a valve (10) particularly at one end (22).
Nebulizer according to claims 2 and 21, provided that the valve (10) is formed or disposed in the outer tube (24).
Nebulizer according to claim 21 or 22, characterized in that the valve (10) has a valve seat (33) which is formed by the transport tube (9) or a valve element or connection element. (40) connected to it.
Nebulizer according to any one of claims 21 to 23, characterized in that the conveying pipe (9) comprises a separately produced, securely connected valve element or connecting element (40). to the transport tube (9), which in particular forms a receiving chamber or valve chamber (31) for a valve element (32) of the valve (10).
Nebulizer according to any one of the preceding claims, characterized in that the transport tube (9) has at least one substantially smooth or cylindrical outer wall (24) and / or an outer diameter which is at least substantially constant over its length.
Nebulizer according to one of the preceding claims, characterized in that the transport tube (9) comprises an outer radial projection (36), particularly a bent edge similar to the flange and / or radial indentation or recess (34). , 37), particularly an annular groove, a depression or an edge.
Nebulizer according to one of the preceding claims, characterized in that the transport tube (9) has an external diameter of 1-2 mm.
Nebulizer according to one of the preceding claims, characterized in that the length of the transport tube (9) is at least 50 mm and / or 50 times the internal diameter of the transport tube (9).
Nebulizer according to one of the preceding claims, characterized in that the transport tube (9) has an internal diameter of 0.1-0.6 mm.
Nebulizer according to one of the preceding claims, characterized in that the transport tube (9) has an external diameter that is at least twice or three times as large as the internal diameter.
Nebulizer according to one of the preceding claims, characterized in that the transport tube (9) has a wall thickness of at least 0.3 mm, in particular substantially 0.5 mm or more.
Nebulizer according to one of the preceding claims, characterized in that the nebulizer (1) is constructed such that the transport tube (9) performs a movement preferably similar to that during fluid removal, transport of generation of fluid pressure and / or atomization.
Nebulizer according to one of the preceding claims, characterized in that the nebulizer has an insertable preference container (3) with a fluid chamber (4) containing the fluid (2) which is open; in particular by fixing or inserting the transport tube (9) to draw fluid (2) from the container (3).
Nebulizer according to one of the preceding claims, characterized in that the nebulizer (1) is constructed as a inhaler, particularly for medical aerosol treatment or for cosmetic purposes, particularly as a perfume atomizer.
A method of producing a thick-walled capillary, particularly as a transport tube (9) for a nebulizer (1), according to one of the preceding claims, the capillary being of double wall construction consisting of several parts. and / or an inner tube (23) being installed in an outer tube (24) to form the capillary.
A method according to claim 35, characterized in that an annular space (26) between the inner tube (23) and the outer tube (24) is gas tightly sealed.
A method according to claim 35 or 36, characterized in that the parts are radially and / or axially welded.
BRPI0613138-7A 2005-06-24 2006-06-23 Nebulizer BRPI0613138A2 (en)
DE102005029746.3A DE102005029746B4 (en) 2005-06-24 2005-06-24 Atomizer
PCT/EP2006/006047 WO2006136427A1 (en) 2005-06-24 2006-06-23 Nebuliser
BRPI0613138A2 true BRPI0613138A2 (en) 2010-12-21
BRPI0613138-7A BRPI0613138A2 (en) 2005-06-24 2006-06-23 Nebulizer
US (2) US8479725B2 (en)
EP (2) EP1893344B1 (en)
JP (2) JP5249752B2 (en)
AR (2) AR055977A1 (en)
AU (1) AU2006261107A1 (en)
BR (1) BRPI0613138A2 (en)
EC (1) ECSP078028A (en)
IL (1) IL186594D0 (en)
MX (1) MX2007015403A (en)
TW (2) TW200711743A (en)
ZA (1) ZA200708563B (en)
CN101873797A (en) * 2007-10-19 2010-10-27 萨可德公司 Compositions and methods for treatment of diabetic retinopathy
DE102009054038A1 (en) * 2009-11-20 2011-05-26 Neoperl Gmbh Water-bearing pipe section with a ventilation duct
WO2011064160A1 (en) * 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
CN104918863B (en) 2013-01-04 2016-12-07 惠伊酒用冷却器有限公司 For aeration from container, distribution fluid the device of regulated fluid temperature
EP2941391A4 (en) 2013-01-04 2016-11-09 Hewy Wine Chillers Llc Apparatus for dispensing a fluid from a container and regulating a temperature thereof
EP3326757A3 (en) * 2016-11-09 2018-11-07 TTI (Macao Commercial Offshore) Limited Cylinder assembly for gas spring fastener driver
CN110099712A (en) 2016-12-21 2019-08-06 勃林格殷格翰国际有限公司 Sprayer and cylindrantherae
GB1408497A (en) * 1972-04-15 1975-10-01 Yoshino Kogyosho Co Ltd Liquid spraying devic3
WO1983000539A1 (en) 1981-08-13 1983-02-17 Balkau, Guenter, Karl, Willi Reciprocatory piston and cylinder machine
IT1240860B (en) 1990-01-23 1993-12-17 Taplast Snc Di Evans Santagiuliana & C. Nebulizer
CH681075A5 (en) 1990-06-08 1993-01-15 Sigg Aluminium & Metallwaren
EP0525842B1 (en) 1991-06-18 1998-02-04 W.L. GORE &amp; ASSOCIATES (UK) LTD Storage vessel
CA2149153A1 (en) 1992-11-11 1994-05-26 Maurice Mckenna An atomiser
GB2310149A (en) * 1996-02-15 1997-08-20 Nomix Chipman Ltd Spray gun
TW565626B (en) * 1996-11-20 2003-12-11 Ebara Corp Liquid feed vaporization system and gas injection device
JP4495352B2 (en) * 1999-04-17 2010-07-07 アー ヴェー ファーバー‐カステル ウンターネーメンスフェルヴァルツング ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニ Applicator
2005-06-24 DE DE102005029746.3A patent/DE102005029746B4/en active Active
2006-06-23 AR ARP060102704A patent/AR055977A1/en unknown
2006-06-23 WO PCT/EP2006/006046 patent/WO2006136426A1/en active Application Filing
2006-06-23 EP EP06762148.2A patent/EP1893344B1/en active Active
2006-06-23 KR KR1020077029840A patent/KR20080017378A/en not_active Application Discontinuation
2006-06-23 RU RU2008101804/12A patent/RU2008101804A/en not_active Application Discontinuation
2006-06-23 CA CA002610740A patent/CA2610740A1/en not_active Abandoned
2006-06-23 WO PCT/EP2006/006047 patent/WO2006136427A1/en active Application Filing
2006-06-23 TW TW095122763A patent/TW200711743A/en unknown
2006-06-23 CN CNA2006800191958A patent/CN101189071A/en not_active Application Discontinuation
2006-06-23 JP JP2008517421A patent/JP5249752B2/en active Active
2006-06-23 JP JP2008517422A patent/JP2008543466A/en active Pending
2006-06-23 CA CA2608296A patent/CA2608296C/en active Active
2006-06-23 EP EP06762147.4A patent/EP1893343B1/en active Active
2006-06-23 BR BRPI0613138-7A patent/BRPI0613138A2/en not_active IP Right Cessation
2006-06-23 AR ARP060102703A patent/AR057400A1/en not_active Application Discontinuation
2006-06-23 TW TW095122794A patent/TW200714365A/en unknown
2006-06-23 AU AU2006261107A patent/AU2006261107A1/en not_active Abandoned
2006-06-23 MX MX2007015403A patent/MX2007015403A/en not_active Application Discontinuation
2006-06-26 US US11/426,411 patent/US8479725B2/en active Active
2006-06-26 US US11/426,406 patent/US7950388B2/en active Active
2007-10-08 ZA ZA200708563A patent/ZA200708563B/en unknown
2007-10-11 IL IL186594A patent/IL186594D0/en unknown
2007-12-17 EC EC2007008028A patent/ECSP078028A/en unknown
ZA200708563B (en) 2008-10-29
AR057400A1 (en) 2007-12-05
US20070029475A1 (en) 2007-02-08
TW200711743A (en) 2007-04-01
EP1893343A1 (en) 2008-03-05
KR20080017378A (en) 2008-02-26
CA2608296C (en) 2014-08-12
RU2008101804A (en) 2009-07-27
US8479725B2 (en) 2013-07-09
CA2608296A1 (en) 2006-12-28
AU2006261107A1 (en) 2006-12-28
ECSP078028A (en) 2008-01-23
JP5249752B2 (en) 2013-07-31
CA2610740A1 (en) 2006-12-28
EP1893343B1 (en) 2014-10-15
AR055977A1 (en) 2007-09-12
DE102005029746A1 (en) 2007-09-13
TW200714365A (en) 2007-04-16
WO2006136427A1 (en) 2006-12-28
JP2008543466A (en) 2008-12-04
IL186594D0 (en) 2008-01-20
MX2007015403A (en) 2008-03-04
CN101189071A (en) 2008-05-28
DE102005029746B4 (en) 2017-10-26
WO2006136426A1 (en) 2006-12-28
EP1893344A1 (en) 2008-03-05
JP2008543684A (en) 2008-12-04
EP1893344B1 (en) 2013-08-21
US20070090205A1 (en) 2007-04-26
US7950388B2 (en) 2011-05-31
CN103272730B (en) 2016-12-07 Nebulizer
CN101918144B (en) 2016-09-14 Nozzle, inhaler and the method producing nozzle
US8561610B2 (en) 2013-10-22 Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber
US8650840B2 (en) 2014-02-18 Reservoir for nebulizer with a deformable fluid chamber
JP2009528862A (en) 2009-08-13 Swirl nozzle
TWI526198B (en) 2016-03-21 Inhalers
KR101297061B1 (en) 2013-08-19 Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
AU2007213819B2 (en) 2012-11-15 Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant
US9265910B2 (en) 2016-02-23 Adapter, inhalation device, and nebulizer
CN102573972B (en) 2014-12-03 Powder inhaler
DE102005029746B4 (en) 2017-10-26 Atomizer
EP2029205A1 (en) 2009-03-04 Atomizer
US20090197841A1 (en) 2009-08-06 Inhalant Propellant-Free Aerosol Formulation